News
Ventyx Biosciences has shared phase 2a data on a Parkinson’s disease prospect that has caught the eye of Sanofi. The readout shows the effect of VTX3232 on biomarkers, providing some of the data that ...
Nielsen, who was diagnosed with MS aged 17, addressed NHS healthcare professionals, local government members and those in the ...
Sanofi successfully prices €1.5 billion bond issue Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches: €750 million ...
Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches: €750 million fixed-rate notes, due June 2029, bearing interest at an ...
French pharmaceutical giant Sanofi announced on Tuesday that Tzield, the world's first and only therapy approved by the ...
Sanofi (NASDAQ: SNY) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Berenberg Bank analyst Luisa Hector ...
Explore more
On June 9, Regeneron Pharmaceuticals and Sanofi (NASDAQ:SNY) announced promising interim results from the open-label Phase 4 ...
STOCKHOLM--Swedish buyout group EQT and French pharmaceutical major Sanofi co-led a $135 million series B financing round in Spanish biotech company SpliceBio. EQT co-led the funding round with Sanofi ...
Looking at licensing deals struck in the past 10 years, Jefferies found that many Big Pharmas do not ultimately follow ...
Merck’s Enflonsia will go up against Sanofi and AstraZeneca’s Beyfortus, which the partners plan to ship out early in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results